Zacks Research lowered shares of GeneDx (NASDAQ:WGS – Free Report) from a strong-buy rating to a hold rating in a report published on Thursday,Zacks.com reports. Wall Street Zen raised shares of GeneDx from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Finally, Weiss Ratings restated a “sell (d)” rating on shares of GeneDx in a research note on Saturday, September 27th. Six equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. GeneDx Company Profile(Get Free Report)GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services.